Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vivos Therapeutics Q4 2023 GAAP EPS $(3.05) Misses $(1.91) Estimate, Sales $3.248M Miss $3.406M Estimate

Author: Benzinga Newsdesk | March 28, 2024 04:42pm
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(3.05) per share which missed the analyst consensus estimate of $(1.91) by 59.69 percent. The company reported quarterly sales of $3.248 million which missed the analyst consensus estimate of $3.406 million by 4.64 percent. This is a 17.77 percent decrease over sales of $3.950 million the same period last year.

Posted In: VVOS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist